Next Article in Journal
Obstructive Sleep Apnea in Patients with Head and Neck Cancer—More than Just a Comorbidity?
Next Article in Special Issue
Overview of the Role of Pharmacological Management of Obstructive Sleep Apnea
Previous Article in Journal
The Free Association Task: Proposal of a Clinical Tool for Detecting Differential Profiles of Semantic Impairment in Semantic Dementia and Alzheimer’s Disease
 
 
Review

Review of the Management of Obstructive Sleep Apnea and Pharmacological Symptom Management

by 1,2,*, 1,2,*, 1,2, 1,2 and 1,2
1
Department of Pharmacy Practice, Texas A&M Rangel College of Pharmacy, 1010 W Ave B, Kingsville, TX 78363, USA
2
Department of Pharmacy Practice, Texas A&M Rangel College of Pharmacy, 59 Reynolds Medical Building, College Station, TX 77843, USA
*
Authors to whom correspondence should be addressed.
Academic Editor: Stuart F. Quan
Medicina 2021, 57(11), 1173; https://doi.org/10.3390/medicina57111173
Received: 29 September 2021 / Revised: 19 October 2021 / Accepted: 26 October 2021 / Published: 28 October 2021
(This article belongs to the Special Issue Obstructive Sleep Apnea: New Perspectives)
Nearly a billion adults around the world are affected by a disease that is characterized by upper airway collapse while sleeping called obstructive sleep apnea or OSA. The progression and lasting effects of untreated OSA include an increased risk of diabetes mellitus, hypertension, stroke, and heart failure. There is often a decrease in quality-of-life scores and an increased rate of mortality in these patients. The most common and effective treatments for OSA include continuous positive airway pressure (CPAP), surgical treatment, behavior modification, changes in lifestyle, and mandibular advancement devices. There are currently no pharmacological options approved for the standard treatment of OSA. There are, however, some pharmacological treatments for daytime sleepiness caused by OSA. Identifying and treating obstructive sleep apnea early is important to reduce the risks of future complications. View Full-Text
Keywords: obstructive sleep apnea (OSA); pharmacotherapy obstructive sleep apnea (OSA); pharmacotherapy
MDPI and ACS Style

Panahi, L.; Udeani, G.; Ho, S.; Knox, B.; Maille, J. Review of the Management of Obstructive Sleep Apnea and Pharmacological Symptom Management. Medicina 2021, 57, 1173. https://doi.org/10.3390/medicina57111173

AMA Style

Panahi L, Udeani G, Ho S, Knox B, Maille J. Review of the Management of Obstructive Sleep Apnea and Pharmacological Symptom Management. Medicina. 2021; 57(11):1173. https://doi.org/10.3390/medicina57111173

Chicago/Turabian Style

Panahi, Ladan, George Udeani, Steven Ho, Brett Knox, and Jason Maille. 2021. "Review of the Management of Obstructive Sleep Apnea and Pharmacological Symptom Management" Medicina 57, no. 11: 1173. https://doi.org/10.3390/medicina57111173

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop